Subject
Radiology, Nuclear Medicine and imaging
Reference37 articles.
1. FDA approves pluvicto/locametz for metastatic castration-resistant prostate cancer;J Nucl Med,2022
2. Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer,2022
3. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3;Scher;J Clin Oncol,2016
4. PSA-based treatment response criteria in castration-resistant prostate cancer: Promises and limitations;Emmenegger;Can Urol Assoc J,2009
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献